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A B S T R A C T
Background: The Italian Society of Infectious and Tropical Diseases performed a survey on the application
of guidelines for the management of persons living with HIV (PLWH), to evaluate current practice and the
yield of screening for latent tuberculosis infection (LTBI) in newly-diagnosed PLWH; in addition, the offer
of preventive therapy to LTBI individuals and the completion rate were analysed.
Materials and methods: Newly-diagnosed PLWH in nine centres were evaluated retrospectively (2016/
2017) using binary and multinomial logistic regression to identify factors associated with LTBI diagnostic
screening and QuantiFERON (QFT) results.
Results: Of 801 patients evaluated, 774 were studied after excluding active TB. LTBI tests were performed
in 65.5%. Prescription of an LTBI test was associated with being foreign-born (odds ratio (OR) 3.19,
p < 0.001), older (for 10-year increments, OR 1.22, p = 0.034), and having a CD4 count <100 cells/mm3 vs
500 cells/mm3 (OR 2.30, p = 0.044). LTBI was diagnosed in 6.5% of 495 patients evaluated by QFT.
Positive results were associated with being foreign-born (relative risk ratio (RRR) 30.82, p < 0.001), older
(for 10-year increments, RRR 1.78, p = 0.003), and having a high CD4 count (for 100 cells/mm3 increments,
RRR 1.26, p < 0.003). Sixteen LTBI individuals started TB preventive therapy and eight completed it.
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HIV infection is a well-known risk factor for progression from
latent tuberculosis infection (LTBI) to active tuberculosis (TB)
(WHO, 2019). In 2018, the World Health Organization (WHO)
estimated 860 000 TB cases worldwide with 251 000 deaths from
TB among HIV-infected persons; this population is defined
hereafter as ‘persons living with HIV’ (PLWH) (WHO, 2019).
Therefore, international guidelines for the management of HIV
infection recommend screening for LTBI diagnosis and treatment
in individuals newly diagnosed with HIV infection (WHO, 2019), or
at least once in HIV-infected individuals (Migliori et al., 2018), or in
selected groups of patients identified as at higher risk of
developing active TB, as in the British guidelines (BHIVA, 2018).
The treatment of LTBI is known to reduce the risk of developing TB
by 60% when using therapy for up to 6 months (isoniazid (INH)
monotherapy for 6 months or rifampicin (RIF) monotherapy for 4
months or the combination of RIF and INH for 3 months), or by up
to 90% using INH monotherapy for 9 months (Fox et al., 2017), and
the clinical benefit is higher among those testing positive in a
screening test (WHO, 2019).
In spite of the existing recommendations, there is evidence that
even in resource-rich countries, a significant proportion of PLWH
are not screened for LTBI diagnosis (WHO, 2019; Evenblij et al.,
2016; Wyndham-Thomas et al., 2016). This may be due to the low
accuracy of LTBI tests to predict the development of active TB (Diel
et al., 2011; Petruccioli et al., 2016a; Goletti et al., 2018a; Goletti
et al., 2018b), to the awareness of the reduction in TB risk in those
on combined antiretroviral therapy (cART) (Girardi et al., 2004;
Girardi et al., 2012), and to the lack of availability of LTBI tests in
clinical centres (CDC, 2011; Web site, 2018).
Current Italian guidelines recommend screening for LTBI
diagnosis by tuberculin skin test (TST) or interferon gamma
release assay (IGRA), either T-SPOT.TB or QuantiFERON (QFT)
(Italian Ministry of Health, 2017). A study conducted in Italy in
2001 (Antonucci et al., 2001) after the first national guidelines on
the diagnosis and treatment of HIV infection recommended TST
screening for newly-diagnosed HIV individuals, reported a sub-
optimal implementation of those recommendations. In particular,
out of 1705 patients studied, 103 were identified as eligible for
preventive therapy. However, this could not be proposed for 20
(five were eventually diagnosed with active TB and 15 had
contraindications to therapy); among the remaining 83, only 40
individuals agreed to start preventive therapy and 29 completed a
full-course regimen. Since then, it appears that no further update
on this issue has been reported.
Therefore, the primary aim of this survey was to evaluate
current practice and the yield of screening for LTBI diagnosis in
persons newly-diagnosed with HIV infection in Italy. The second-
ary objectives were to evaluate whether preventive therapy was
offered to those diagnosed with LTBI and its completion rate.
Materials and methods
Study design
The protocol of this multicentre retrospective observational
study was developed by an ad hoc group of the Italian Society for
Infectious and Tropical Disease (SIMIT). The survey was sent to the
infectious diseases centres in Italy. Among them, nine centres, alllocated in public hospitals and/or public universities, volunteered
to participate. Six centres were in northern Italy and three in
central Italy. These centres account for the diagnosis and cure of at
least 10% of persons newly-diagnosed with HIV infection in Italy,
based on the 2018 national report (Istituto Superiore di Sanità,
2019), showing 3673 and 3561 new diagnoses in 2016 and 2017,
respectively.
Persons newly-diagnosed with HIV infection in participating
centres were enrolled retrospectively from January 2016 to
December 2017. All recruited patients were naïve to cART, by
definition. For each patient, the following information was
collected: sex, age, country of birth, HIV transmission category,
hepatitis B virus (HBV) serology and antigen detection (HBsAg/Ab)
and hepatitis C virus (HCV) serology, first CD4 cell count, first HIV
viremia, AIDS diagnosis, TB diagnosis, chest X-rays, LTBI diagnosis,
and preventive therapy uptake.
For the purposes of this analysis, it was considered that the
screening for LTBI diagnosis was performed when the result of a
TST or of an IGRA (QFT-Gold In Tube or QFT-Plus; Qiagen, Hilden,
Germany) was available within 6 months from the first HIV-
positive test and before starting cART. In the text, the acronym
‘QFT’ is used to indicate either IGRA test, unless specified
otherwise.
Statistical analysis
The median and interquartile range (IQR) was calculated for
continuous measures. The Chi-square test or Fisher’s exact test
was used for categorical variables. The Kruskal–Wallis test was
used for comparisons among several groups. Univariable and
multivariable binary logistic regression were used to identify
factors associated with screening for LTBI diagnosis, reporting the
odds ratio (OR), 95% confidence interval (CI), and p-value.
Univariable and multivariable multinomial logistic regression
analyses were used to identify factors associated with positive and
with indeterminate QuantiFERON results, assuming negative
results as the reference category, reporting the relative risk ratio
(RRR), 95% CI, and p-value. Multivariable models included
variables with a p-value less than 0.2 in the univariable analysis
together with sex, age, and born in Italy. A p-value less than 0.05
was considered significant. The data analysis was performed using
Stata Statistical Software Release 15, 2017 (StataCorp LLC, College
Station, TX, USA).
Results
Population characteristics of the newly-diagnosed HIV-infected
patients who underwent screening for LTBI diagnosis
A total of 801 newly-diagnosed PLWH coming from nine
centres in Italy located in the north and centre of the country
were evaluated. Active TB was diagnosed in 27 individuals
(3.4%) (Figure 1). Excluding those with active TB, 774
individuals remained eligible for screening for an LTBI diagno-
sis (Table 1). The median age of these patients was 38 years (IQR
30–47 years); 71.8% were born in Italy, 52.1% were men who
have sex with men (MSM), and 16.8% had an AIDS diagnosis. The
median CD4 count was 319 cells/mm3 (IQR 133–540 cells/mm3)
and the median HIV RNA was 4.9 log10 copies/ml (IQR 4.2–5.4
log10 copies/ml) (Table 1).
Figure 1. Flow chart of enrolled newly HIV diagnosed patients in 9 Italian centres
(2016–2017).
Table 2
Results of the patients without active TB screened for LTBI by centre.
Centre Screened for LTBI by QFT or TST Screened for LTBI by QFT
n (%) n (%)
1 101 (88.6) 101 (88.6)
2 4 (8.9) 0
3 32 (100) 32 (100)
4 112 (84.2) 112 (84.2)
5 48 (85.7) 48 (85.7)
6 172 (58.9) 171 (58.6)
7 0 0
8 30 (93.7) 30 (93.7)
9 8 (20.5) 1 (2.6)
Total 507 (65.5) 495 (63.9)
TB, tuberculosis; LTBI, latent tuberculosis infection; TST, tuberculin skin test; QFT,
QFT-IT or QFT-Plus (QFT-P).
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screening for LTBI diagnosis
The performance of screening was evaluated in the 774
individuals studied. It was found that a LTBI test (TST or QFT)
was performed in only 507 individuals (65.5%) and that one centre
did not perform any of these assays (Table 2). The majority, 495
patients, were evaluated by QFT, although two centres did not use
this test at all and one centre performed it in less than 5% of the
patients (Figure 1; Table 2). HBV and HCV screening are also
recommended based on current HIV guidelines (Italian Ministry of
Health, 2017; WHO, 2016; EACS, 2019). Therefore, HBV and HCV
screening were evaluated among the 774 individuals studied.
Considering all centres, HBV serology/HBsAg detection and HCV
serology were performed in at least 95.5% of the patients (range
95.5–100%, overall 97.8% and 98.2%, respectively).
Factors associated with LTBI test prescription
Factors associated with the prescription of an LTBI test were
analysed. To correctly identify these factors, the two centres in
which the test was performed in either 100% or in less than 5% of
enrolled individuals were excluded from this analysis (Table 2).Table 1












North West 1 114 37 (29–47) 75 (65.8) 58 (50.9) 
2 45 36 (28–50) 31 (68.9) 14 (31.1) 
Lombardy 3 32 41 (33–55) 18 (56.2) 15 (46.9) 
4 133 40 (30–50) 90 (67.7) 46 (34.6) 
North East 5 56 33 (29–45) 34 (60.7) 34 (60.7) 
Latium 6 292 36 (29–47) 226 (77.4) 195 (66.8) 
7 31 40 (31–45) 20 (64.5) 8 (25.8) 
8 32 38 (29–49) 30 (93.7) 12 (37.5) 
9 39 40 (32–52) 32 (82.0) 21 (53.8) 
Total 774 38 (30–47) 556 (71.8) 403 (52.1) 
IQR, interquartile range; MSM, men who have sex with men; TB, tuberculosis. CD4 coun
done in 749 patients; HIV RNA is reported if tested within 90 days from the date of HAmong the 711 patients included in this analysis (Table 3), 475
(66.8%) were screened by QFT or TST. By multivariable analysis, also
adjusted for centre of enrolment, it was found that the test was
more likely to be performed in foreign-born individuals (OR 3.19,
p < 0.001), in older patients (for 10-year increments, OR 1.22,
p = 0.034), and in individuals with a CD4 cell count <100 vs 500
cells/mm3 (OR 2.30, p = 0.044) (Table 3).
Characteristics of the HIV-infected patients with a positive or
indeterminate QFT result
Considering that only a few patients were screened by TST, only
those screened by QFT were further analysed. A positive result was
found in 32 (6.5%) of the 495 patients evaluated by QFT (Figure 1;
Table 4). Among them, four (12.5%) were from a low TB endemic
country (<10/100 000 inhabitants; three from Italy and one from
Cuba), while eight (25%) were from TB high endemic countries
(100/100 000 inhabitants) and 20 (62.5%) were from TB
intermediate endemic countries (TB incidence 11 and <99/100
000 inhabitants and 100/100 000 inhabitants) (WHO, 2018;
Lonnroth et al., 2015); all had CD4 cell counts higher than 100 cells/
mm3. The majority were male, with the most frequent risk factor
for HIV being MSM. None had AIDS, and diagnoses were equally
distributed in 2016 and 2017 using either QFT-IT or QFT-P (Table 5).
Indeterminate results were found in 3.2% (16/495) of the patients
evaluated by QFT (Table 4).
On multivariable analysis, when compared to a negative QFT
result, a positive result was significantly associated with being
foreign-born (RRR 30.82, p < 0.001), older (for 10-year increments,
RRR 1.78, p = 0.003), and having a CD4 cell count 100 cells/mm3
(for 100 cells/mm3 increments, RRR 1.26, p = 0.003). The indeter-
minate result was significantly associated only with a low (<100)out active TB, by enrolment centre.
n AIDS diagnosis, n
(%)
CD4 cell count, median (IQR)
cells/mm3
Log10 HIV RNA, median
(IQR)
19 (16.7) 298 (116–557) 4.8 (4.2–5.4)
7 (15.6) 285 (133–455) 5.0 (4.1–5.4)
17 (53.1) 102 (39–297) 5.1 (4.7–5.9)
30 (22.6) 338 (129–597) 4.8 (4.1–5.3)
9 (16.1) 376 (98–592) 4.8 (4.3–5.3)
25 (8.6) 387 (219–563) 4.9 (4.3–5.4)
0 205 (62–332) 4.9 (4.2–5.4)
11 (34.4) 252 (73–463) 4.9 (4.4–5.6)
12 (30.8) 225 (51–328) 5.1 (4.1–5.7)
130 (16.8) 319 (133–540) 4.9 (4.2–5.4)
ts are reported if tested within 90 days from the date of HIV diagnosis, and this was
IV diagnosis, and this was done in 745 patients.
Table 3
Characteristics of the patients screened by QuantiFERON or TST among the 711 subjects.
Characteristics Screening by QFT or TST
Total Done Binary logistic regression model
711 475 (66.8%) Univariable Multivariablea
n (%) n (%) OR (95% CI) p-Value aOR (95% CI) p-Value
Sex
Male 557 (78.3) 365 (76.8) 1 1
Female 133 (18.7) 91 (19.2) 1.14 (0.76–1.71) 0.527 0.55 (0.28–1.05) 0.070
Transgender 21 (3.0) 19 (4.0) 5.0 (1.15–21.7) 0.032 3.19 (0.65–15.57) 0.152
Age, years
Median (IQR) 37 (29–47) 38 (30–48) 1.10 (0.96–1.26) 0.179 1.22 (1.01–1.46) 0.034
Born in Italy
Yes 519 (73.0) 320 (67.4) 1 1
No 192 (27.0) 155 (32.6) 2.52 (1.7–3.75) <0.001 3.19 (1.83–5.55) <0.001
HIV risk
MSM 380 (53.4) 239 (50.3) 1 1
Heterosexual 240 (33.8) 165 (34.7) 1.30 (0.92–1.83) 0.137 1.60 (0.88–2.89) 0.122
IDU 20 (2.8) 14 (3.0) 1.38 (0.52–3.66) 0.522 1.16 (0.33–4.01) 0.819
Other/unknown 71 (10.0) 57 (12.0) 2.40 (1.29–4.47) 0.006 1.43 (0.68–3.02) 0.347
CD4b T cells/mm3
<100 127 (17.9) 97 (20.4) 1.63 (0.99–2.69) 0.057 2.30 (1.02–5.16) 0.044
100–199 82 (11.5) 62 (13.1) 1.56 (0.87–2.79) 0.133 1.98 (0.95–4.13) 0.070
200–499 274 (38.5) 165 (34.7) 0.76 (0.52–1.11) 0.159 1.05 (0.67–1.64) 0.820
500 206 (29.0) 137 (28.8) 1 1
Unknown 22 (3.1) 14 (3.0) 0.88 (0.35–2.20) 0.787 0.94 (0.30–2.94) 0.913
HIV RNAb log10
Median (IQR) 4.9 (4.2–5.4) 4.9 (4.3–5.4) 1.07 (0.91–1.25) 0.410
AIDS diagnosisc
No 598 (84.1) 388 (81.7) 1 1
Yes 113 (15.9) 87 (18.3) 1.81 (1.13–2.90) 0.013 1.04 (0.46–2.33) 0.924
Year of HIV diagnosis
2016 379 (53.3) 244 (51.4) 1 1
2017 332 (46.7) 231 (48.6) 1.27 (0.92–1.73) 0.142 1.40 (0.95–2.06) 0.085
aOR, adjusted odds ratio; CI, confidence interval; IDU, injecting drug user; IQR, interquartile range; MSM, men who have sex with men; OR, odds ratio; QFT, QFT-IT or QFT-Plus
(QFT-P); TST, tuberculin skin test. Observations from centres where screening was performed on more than 5% and less than 100% of the enrolled persons were used in this
analysis.
a All variables with a p-value less than 0.2 in the univariable analysis were included in the multivariable model; estimations were also adjusted for centre of enrolment. Age
was considered for 10-year increments.
b CD4 and RNA were evaluated only if available within 90 days from HIV diagnosis.
c AIDS if diagnosed within 90 days from HIV diagnosis.
Table 4
Results of the screening for LTBI done by QFT, by centre.
Centre QuantiFERON results among 495 patients tested by QFT
Negative Positive Indeterminate Total
n (%) n (%) n (%) n (%)
1 92 (91.1) 5 (4.9) 4 (4.0) 101 (100)
2 – – – –
3 30 (93.7) 1 (3.1) 1 (3.1) 32 (100)
4 104 (92.9) 5 (4.5) 3 (2.7) 112 (100)
5 42 (87.5) 5 (10.4) 1 (2.1) 48 (100)
6 152 (88.9) 16 (9.4) 3 (1.7) 171 (100)
7 – – – –
8 26 (86.7) 0 4 (13.3) 30 (100)
9 1 (100) 0 0 1 (100)
Total 447 (90.3) 32 (6.5) 16 (3.2) 495 (100)
LTBI, latent tuberculosis infection; QFT, QFT-IT or QFT-Plus (QFT-P).
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(Table 6).
Offer of preventive therapy and completion of therapy in individuals
with LTBI
Preventive therapy was offered to 19/32 individuals (59.4%)
(Figure 2). Among them, 3/19 (15.8%) did not start therapy because
of chronic HBV infection or self-declared poor compliance. Among
the 16 (84.2%) who started preventive therapy, eight (50%)
completed treatment, while of the remaining eight, one hadsuspected TB lymphadenitis, one was lost to follow-up, and six
were poorly compliant.
Preventivetherapywasnotproposedto13/32(40.6%).Thiswasdue
to transfer from the clinical centre or loss to follow-up (6/13), decision
to delay the start of treatment (3/13), HBV co-infection (2/13), cancer
(1/13), or an unconfirmed QFT diagnosis after test repetition (1/13).
Discussion
In this multicentre study involving nine Italian HIV centres, it was
found that screening for a LTBI diagnosis was performed in
approximately 65% of individuals newly-diagnosed with HIV. This
screening was more frequently performed among foreign-born
individuals, older individuals, and individuals with a low CD4 cell
count. LTBI was detected in 6.5% of screened individuals, with a higher
riskamongforeign-bornindividuals,olderindividuals,andindividuals
with a CD4 cell count higher than 100 cells/mm3. Indeterminate
resultswereobservedin3.2%of individualsandwereassociatedwitha
low CD4 cell count. Among LTBI individuals, 60% were offered
preventive therapy, 50% started treatment, and 25% completed it.
These results indicate that screening for LTBI diagnosis is not
consistently performed in PLWH. Furthermore, TB preventive therapy
is not offered to eligible LTBI individuals and compliance with therapy
is poor. Therefore, we need to perform an in-depth analysis of the
reasons underlying the observed suboptimal prescription of tests and
of the criteria for selecting the population to target for LTBI screening,
as has already been conducted in other countries (BHIVA, 2018;
Evenblij et al., 2016).
Table 5
QFT results and patient characteristics for the 495 patients screened by QFT.
Characteristics QuantiFERON result
Negative (447) Positive (32) Indeterminate (16) Total (495)
n (%) n (%) n (%) n (%)
Sex
Male 351(78.5) 18 (56.2) 12 (75.0) 381 (77.0)
Female 81(18.1) 6 (18.8) 4 (25.0) 91 (18.4)
Transgender 15 (3.4) 8 (25.0) 0 23 (4.6)
Age, years
Median (IQR) 38 (30–48) 37.5 (30–49) 51.5 (43.5–58.5) 39 (30–48)
Born in Italy
Yes 316 (70.7) 3 (9.4) 15 (93.8) 334 (67.5)
No 131(29.3) 29 (90.6) 1 (6.2) 161 (32.5)
HIV risk
MSM 229 (51.2) 17 (53.1) 5 (31.2) 251 (50.8)
Heterosexual 148 (33.1) 8 (25.0) 8 (50.0) 164 (33.1)
IDU 13 (2.9) 2 (6.2) 0 15 (3.0)
Other/unknown 57 (12.8) 5 (15.7) 3 (18.8) 65 (13.1)
CD4a T cells/mm3
<100 93 (20.8) 0 15 (93.8) 108 (21.8)
100–199 56 (12.5) 3 (9.4) 1 (6.2) 60 (12.1)
200–499 162 (36.2) 8 (25.0) 0 170 (34.3)
500 116 (26.0) 21(65.6) 0 137 (27.7)
Unknown 20 (4.5) 0 0 20 (4.0)
HIV RNAa log10
Median (IQR) 4.93 (4.34–5.43) 4.3 (3.89–5.06) 5.53 (5.26–5.9) 4.93 (4.3–5.43)
AIDS diagnosisb
No 359 (80.3) 32 (100) 3 (18.8) 394 (79.6)
Yes 88 (19.7) 0 13 (81.2) 101 (20.4)
Year of HIV diagnosis
2016 233 (52.1) 15 (46.9) 9 (56.2) 257 (51.9)
2017 214 (47.9) 17 (53.1) 7 (43.8) 238 (48.1)
QFT type
QFT In Tube 276 (61.7) 18 (56.2) 10 (62.5) 304 (61.4)
QFT Plus 171 (38.3) 14 (43.8) 6 (37.5) 191 (38.6)
IDU, injecting drug user; IQR, interquartile range; MSM, men who have sex with men; QFT, QFT-IT or QFT-Plus (QFT-P).
a CD4 and RNA evaluated only if available within 90 days from QuantiFERON test.
b AIDS if diagnosed within 90 days from HIV test.
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PLWH was performed significantly more frequently in foreign-
born individuals coming from high TB incidence countries. This is
in agreement with what has been observed in other European
countries, such as the Netherlands (Evenblij et al., 2016), Belgium
(Wyndham-Thomas et al., 2016), and Switzerland (Elzi et al., 2007),
as well as in non-European countries, such as Australia (Doyle
et al., 2014). In contrast, a study performed in the United States
demonstrated an association between the request for screening for
LTBI diagnosis and poverty (Reaves et al., 2017). This is a very
interesting issue; however this parameter was not evaluated in our
survey. The low implementation of LTBI screening is likely due to
the low perception of TB risk in PLWH (Evenblij et al., 2016), and to
the awareness of the inaccuracy of LTBI tests, which can give false-
negative results in immunosuppressed persons (Goletti et al.,
2014; Goletti et al., 2007; Vincenti et al., 2007) and are inadequate
to predict progression to disease (Diel et al., 2011; Petruccioli et al.,
2016a; Goletti et al., 2018a; Goletti et al., 2018b). The accuracy of
LTBI tests improves if a selected population known to have a higher
probability to progress to active disease is identified, as
recommended in the recent guidelines of the British HIV
Association (BHIVA) (BHIVA, 2018). BHIVA recommends testing
PLWH for LTBI diagnosis if they come from countries of high and
intermediate TB incidence, with particular attention to individuals
recently exposed to TB. BHIVA also suggests including PLWH from
low-incidence countries in the screening if they have additional TB
risk factors. This is a very pragmatic approach and has a high
chance of being accepted and followed by HIV specialists.
There is no reference test for the diagnosis of LTBI. The tests
currently available assess the presence of an immune response toMycobacterium tuberculosis antigens in vivo (TST) or ex vivo (IGRA).
In a large European cohort study with more than 1700 patients
with a wide variety of types of immunosuppression, the
application of IGRAs among HIV-infected individuals led to a
higher number of positive results compared to TST (Sester et al.,
2014). This is most likely one of the reasons why the majority of
clinicians use IGRAs more frequently than the TST. Additional
reasons are related to the wider availability of IGRAs in hospitals
compared to TST, and also to the increased acceptability of the
blood test by patients (Hirsch-Moverman et al., 2013). It should be
noted that in Italy, TB screening was hampered between 2015 and
2016 by an inability to find the TST or the failure to perform IGRAs
in the hospitals, which explains the lack of prescription for
screening in one centre (Web site, 2018).
Regarding the results, the IGRA allows so-called indeterminate
responses to be identified, which are due either to a high interferon
gamma (IFN-g) background concentration in the negative control
or a low IFN-g value in the positive control, alerting the clinician
not to exclude LTBI on the basis of the test results. In the present
study, a low proportion of indeterminate results were found and
these were mainly associated with older age, low CD4 cell counts,
and AIDS status. The observed results are in agreement with the
literature (Sester et al., 2014).
The proportion of positive responses did not differ when using
the old version of QFT-IT in 2017 and the new version of QFT-Plus in
2018. It is known that the new QFT-Plus version has additional
peptides specific for CD8 T-cells (Petruccioli et al., 2016b; QIAGEN,
2020) and this may improve the ability to detect LTBI in HIV-
infected individuals. However, this study was not designed to
evaluate its diagnostic yield.
Table 6
Factors associated with QFT score in the 495 patients screened by QFT.
Characteristics Multinomial logistic regression modela
Univariable Multivariableb
QFT positive QFT indeterminate QFT positive QFT indeterminate
RRR (95% CI) p-Value RRR (95% CI) p-Value RRR (95% CI) p-Value RRR (95% CI) p-Value
Sex
Male 1 1 1 1
Female 1.44 (0.56–3.75) 0.451 1.44 (0.45–4.59) 0.534 0.73 (0.25–2.12) 0.558 2.78 (0.66–11.79) 0.166
Transgender 10.40 (3.90–27.72) <0.001 0 (0) 0.992 1.90 (0.64–5.69) 0.250 0 (0) 0.999
Age, by 10-year increase 0.98 (0.71–1.33) 0.877 2.08 (1.34–3.23) 0.001 1.78 (1.21–2.62) 0.003 1.53 (0.85–2.74) 0.152
Born in Italy
Yes 1 1 1 1
No 23.32 (6.98–77.88) <0.001 0.16 (0.02–1.23) 0.078 30.82 (8.25–115.18) <0.001 0.15 (0.02–1.41) 0.098
HIV risk
MSM 1 1
Heterosexual 0.73 (0.31–1.73) 0.472 2.48 (0.79–7.71) 0.118
IDU 2.07 (0.43–9.94) 0.363 0 (0) 0.987
Other/unknown 1.18 (0.42–3.34) 0.753 2.41 (0.56–10.39) 0.238
CD4c T cells/mm3 1.26 (1.13–1.41) <0.001 0.09 (0.02–0.37) 0.001 1.26 (1.08–1.46) 0.003 0.11 (0.03–0.48) 0.003
HIV RNAc (log10 copies/ml) 0.59 (0.41–0.84) 0.003 2.23 (1.26–3.93) 0.006 0.87 (0.53–1.41) 0.570 1.43 (0.58–3.52) 0.434
AIDS diagnosisd
No 1 1 1 1
Yes 0 (0) 0.986 17.68 (4.93–63.4) <0.001 0 (0) 0.994 2.26 (0.54–9.53) 0.266
Year of HIV diagnosis
2016 1 1
2017 1.23 (0.6–2.53) 0.566 0.85 (0.31–2.31) 0.746
QFT type
QFT In Tube 1 1
QFT In Tube 1.26 (0.61–2.59) 0.538 0.97 (0.35–2.71) 0.951
CI, confidence interval; IDU, injecting drug use; MSM, men who have sex with men; QFT, QFT-IT or QFT-Plus (QFT-P); RRR, relative risk ratio.
a In the multinomial logistic model, a negative result was the base outcome, and CD4 for 100 cells/mm3 increment.
b Variables with a p-value less than 0.2 in the univariable analysis were included in the multivariable model.
c CD4 and RNA evaluated only if available within 90 days from QuantiFERON test.
d AIDS if diagnosed within 90 days from HIV test.
Figure 2. Offer of preventive therapy and completion of therapy in individuals with LTBI.
D. Goletti et al. / International Journal of Infectious Diseases 92 (2020) 62–68 67cART has been shown to reduce the risk of developing TB in
PLWH;however, the risk of TBin HIV-infected individualsusing cART
remains higher than the risk in non-HIV-infected individuals (Lawn
et al., 2009; Gupta et al., 2015; Gupta et al., 2012). Therefore, in those
who are found to be LTBI-positive, TB preventive therapy should be
offered for its beneficial effects in reducing the reactivation of TB also
in PLWH on cART (Rangaka et al., 2014), making LTBI screening and
treatment a worthwhile strategy also in countries with good access
to and uptake of cART. In the present study, TB preventive therapy
was offered to only 60% of the eligible patients. This was due mainly
to the presence of comorbidities and low patient compliance with
the long preventive treatment. New therapeutic options have
recently been proposed; in particular, a 1-month regimen of
rifapentine plus INH could be very attractive (Swindells et al.,2019). This newly approved regimen could also be useful in
increasing the completion rate of LTBI treatment. Indeed, in our
cohort, only 25% of those with LTBI completed treatment. This new
short regimen could be of added value for clinicians continuing or
increasing the screening of newly diagnosed HIV patients for LTBI,
considering the possibility of offering a short and effective treatment
to those in need.
Interestingly, on evaluating the prescription of other recom-
mended screening tests, such as those for HBV and HCV serology, it
was found that these were more frequently performed (in at least
97.8% of PLWH).
Limitations of the study are the retrospective approach used and
the partial coverage of the centres caring for PLWH in Italy. However,
this is the first multicentre study on the evaluation of LTBI screening
68 D. Goletti et al. / International Journal of Infectious Diseases 92 (2020) 62–68in newly-diagnosed HIV-infected individuals, and it lays the basis to
assess the current incidence of LTBI in PLWH in Italy.
In conclusion, this multicentre study found that screening for
LTBI diagnosis was performed in only 65.5% of newly-diagnosed
HIV-infected patients. LTBI tests were mainly prescribed to
foreign-born patients. The majority (87.5%) of LTBI individuals
came from countries with a high or intermediate TB incidence. An
in-depth analysis of the reasons related to the suboptimal
prescription of tests and of the population to target for LTBI
screening is envisaged.
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